Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01966328
Other study ID # VMA-001
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received October 14, 2013
Last updated May 21, 2015
Start date October 2013

Study information

Verified date May 2015
Source Ophthalmic Consultants of Boston
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This research is studying the effect that Resolvine injection will have on patients with vitreomacular adhesion.


Description:

This research is studying the effect that Resolvine injection will have on patients with vitreomacular adhesion. The investigators propose that intravitreal injection of Resolvine® 36% will: 1)Result in release of the vitreous adhesion to the macula in subjects with symptomatic vitreomacular attachment (VMA). 2)The Release of the VMA will create a measurable and favorable retinal change. 3) The release of vitreomacular traction may also result in visual acuity improvement within the short time frame of this study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Male or female subjects, 18 years of age or older

2. Willing and able to return for all study visits

3. Willing and able to provide written informed consent

4. Have symptomatic VMA.

5. If both eyes are found to have Anatomic VMA the eye with lower visual acuity will be declared the study eye.

Exclusion Criteria:

1. Subjects with high myopia in the study eye (axial length greater than or equal to 26.0 millimeters by ultrasound or spherical equivalent at the spectacle plane greater than -8.0 diopters)

2. Subjects who have monocular vision or contralateral vision of 20/400 or worse BCVA in the non-study eye

3. Subjects with a history of retinal detachment or tear in the study eye

4. Subjects who have PVD in the study eye at Baseline (Grade III or greater PVD by B-scan)

5. Subjects with unstable IOP (i.e. > 30 mmHg in the past six months) or IOP of > 21 mm Hg at enrollment, under medical control. Subjects may be on topical medications to control their IOP but may not stop or start a prostaglandin type or epinephrine based drug during the study.

6. Subjects with an aphakic study eye or if pseudophakic, cataract extraction surgery less than 6 months prior to study enrollment

7. Subjects with a history of ocular trauma of any type in the study eye

8. Subjects with media opacities or abnormalities that would preclude observation of the retina in the study eye per the investigator's judgment

9. Subjects that have undergone any previous vitrectomy (either anterior or pars plana vitrectomy) in the study eye

10. Subjects with a history of cataract surgery complications in the study eye

11. Subjects that have undergone previous photocoagulation of the retina in the study eye

12. Subjects with any evidence or history of either nonproliferative or proliferative diabetic retinopathy (NPDR) or (PDR) in the study eye

13. Subjects with an anticipated need for cataract extraction in the study eye within the next 6 months

14. Subjects with congenital eye malformations

15. Subjects with recurrent uveitis or history of uveitis in either eye

16. Subjects with ongoing ocular infection or inflammation in the study eye

17. Subjects who are pregnant or nursing. Subjects of child bearing ages will undergo pregnancy testing.

18. Subjects that are currently participating in any other investigational research study

19. Subjects who are too ill to be likely to complete the entire study

20. Subjects who have undergone major surgery within the last 6 months (systemic or ocular) or who are likely to require major surgery in the upcoming 6 months

21. Subjects who are uncontrolled diabetics (HbA1/C > 10%) with significant morphological pathology at the time of enrollment

22. Subjects with macular holes Stage 2 or greater as determined by OCT, B-scan ultrasound and clinical examination

23. Subjects with epiretinal membrane (ERM) at the area of attachment as determined by OCT

24. Subjects that have received other intravitreal injection therapy within thirty (30) days of treatment with Resolvine®

25. Subjects that have received more than one Jetrea injection in the study eye

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
36% Resolvine Intravitreal Injection
36% Resolvine Intravitreal Injection
9% Resolvine Intravitreal Injection
9% Resolvine Intravitreal Injection

Locations

Country Name City State
United States Retina-Vitreous Associates Medical Group Beverly Hills California
United States Ophthalmic Consultants of Boston Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Jeffrey S Heier Kato Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of 36% Resolvine Injection versus 9% Resolvine Injection The primary objective of this study is to evaluate the safety of an active arm treated with Resolvine® 36%, which may contain up to two 100-microliter intravitreal injections, in comparison to a control arm treated with Resolvine 9%, which may contain up to two 100-microliter injections, in subjects with VMA. Cumulative adverse event rates for each arm will be evaluated. After all patients have completed the 6 month follow-up. No
Primary Efficacy of 36% Resolvine Injection versus 9% Resolvine Injection The primary objective of this study is to evaluate the efficacy of an active arm treated with Resolvine® 36%, which may contain up to two 100-microliter intravitreal injections, in comparison to a control arm treated with Resolvine 9%, which may contain up to two 100-microliter injections, in subjects with VMA. Efficacy will be measured by the percent of patients whose VMA has released after treatment. After all patients have completed the 6 month follow-up No
Secondary Inducement of PVD These analyses will compare the efficacy an active arm treated with Resolvine® 36%, which may contain up to two 100-microliter intravitreal injections, to a control arm treated with Resolvine 9%, which may contain up to two 100-microliter injections, to assess inducement of a more extensive PVD over the study period as demonstrated by Trese Grade III or higher B-Scan Ultrasound and OCT. After all patients have completed the 6 month follow-up No
Secondary Improved Eye Function These analyses will assess a parameter of improved eye function as calculated by either the reduction in the retinal thickness of at least 10% over baseline at Day 0 as quantified by OCT, or an improvement in visual acuity of more than 10% over baseline at day 0 as quantified by ETDRS. After all patients have completed the 6 month follow-up. No
See also
  Status Clinical Trial Phase
Completed NCT06038968 - Methotrexate Infusion and Intrasilicone Injection During Diabetic Vitrectomy Early Phase 1
Terminated NCT04300881 - Treatment of Post-Ocriplasmin Therapy Vitreolysis Induced Subretinal Fluid With Eplerenone (Mineralocorticoid Antagonists) Phase 2
Completed NCT03647267 - Effects of Pneumatic Vitreolysis on Vitreomacular Traction Phase 3
Recruiting NCT02290795 - Vitreopapillary Interface and Optic Disc Morphology N/A
Completed NCT05287269 - Ocular Coherence Tomography During Cataract Assessment
Completed NCT02322229 - Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion Phase 4
Completed NCT05517473 - Efficacy and Safety Evaluation of MONOBLUE DUAL View and MONOBLUE ILM View Vital Stains
Completed NCT01162356 - Prospective Retinal and Optic Nerve Vitrectomy Evaluation (PROVE) Study N/A
Recruiting NCT05588037 - Combined Vitrectomy and Femtosecond Laser-assisted Cataract Surgery N/A
Completed NCT00435539 - A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt) Phase 2
Recruiting NCT00892619 - Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel N/A
Completed NCT02035748 - Assessment of Patients Treated With JETREA® for Vitreomacular Traction Phase 4
Recruiting NCT05860985 - Zeiss RESIGHT Disposable Lenses Evaluation Study N/A